Flex (FLEX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Mueller Water Products (MWA) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Esco Technologies (ESE) possesses solid growth attributes, which could help it handily outperform the market.

StoneX Group (SNEX) could produce exceptional returns because of its solid growth attributes.

PrairieSky Royalty Ltd. (PSK:CA) Q4 2025 Earnings Call Transcript

XPLR Infrastructure, LP Common Units (XIFR) Q4 2025 Earnings Call Transcript

Truist Financial Corporation (TFC) Presents at UBS Financial Services Conference 2026 Transcript

Cincinnati Financial Corporation (CINF) Q4 2025 Earnings Call Transcript

LiveWire Group, Inc. (LVWR) Q4 2025 Earnings Call Transcript

Unless you've been living under a rock, you'd be aware of the growing dominance of artificial intelligence.

The latest departures follow a trend of leadership instability across Musk's portfolio of companies. Roughly 66% of Musk's direct reports have left since 2021, according to analysis by the Financial Times.

JAKKS Pacific remains a "Buy" despite sharp revenue and profit declines, supported by a robust balance sheet and attractive valuation. JAKK's Q3 revenue plunged 34%, mainly due to the Toys/Consumer Products segment's weakness from delayed retailer orders and tariff-driven price hikes. Recent licensing wins, such as Demon Slayer and Hershey partnerships, position JAKK for future growth as market conditions normalize.

Jumia Technologies AG – ADR (NYSE: JMIA) shares are trading sharply lower Tuesday afternoon after the company reported worse-than-expected fourth-quarter EPS results.

Micron's stock has dropped on competitive concerns, but a Deutsche Bank analyst thinks the company can benefit from a memory boom that's “still not well understood” by many investors.

LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming March 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired CoreWeave, Inc. (“CoreWeave” or the “Company”) (NASDAQ: CRWV) securities between March 28, 2025 and December 15, 2025, inclusive (the “Class Period”).

Krystal Biotech maintains a 'Strong Buy' rating, driven by robust VYJUVEK sales and significant pipeline progress. Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated patients. A single registrational trial of KB707 plus chemotherapy versus chemotherapy alone may support regulatory filing, with interim analysis expected in H2 2026.

Alphabet's debt sale is set to top $30 billion, according to people familiar with the matter. The company increased the size of the offering, which had been expected to land at $20 billion, as investor demand strengthened.

Gold and silver remain in a secular bull market, with recent pullbacks presenting attractive entry points for long-term investors. Structural demand-supply imbalances, particularly surging investment and central bank demand, underpin the bullish thesis for both metals. Investor allocations to gold and silver remain historically low, suggesting the trade is far from crowded and has significant upside potential.

SPGI posts mixed Q4 2025 results as EPS misses while revenues top estimates, with segment growth offset by recent stock declines.

BCS' Q4 net income jumps 24% as credit impairment charges fall and revenues rise despite higher expenses.